CVS Health Beats Q2 Estimates, Raises Full-Year Guidance

CVS Health reported Q2 2026 results that exceeded analyst forecasts across key metrics. Adjusted EPS came in at $2.58, compared to the consensus estimate of $1.85. Net revenue reached $106.1 billion, surpassing the expected $99.97 billion, while comparable sales rose 2.6% versus an estimated 2.19%. Adjusted operating income was $5.16 billion, well above the $3.93 billion forecast.

Based on the strong performance, the company raised its full-year outlook. It now sees FY adjusted EPS in the range of $7.90 to $8.10, up from the prior $7.30 to $7.50 and above the $7.45 estimate. Full-year revenue is anticipated to be at least $414 billion, an increase from the previous guidance of at least $405 billion.

Cash flow from operations is projected at a minimum of $11.5 billion, exceeding the $10.38 billion estimate. The guidance upgrade reflects improved operational momentum and confidence in the remainder of the year.